Baryonic resonances close to the Kbar-N threshold: the case of Sigma(1385)^+ in pp collisions

We present results of an exclusive measurement of the first excited state of the Sigma hyperon, Sigma(1385)^+, produced in p+p -> Sigma^+ + K^+ + n at 3.5 GeV beam energy. The extracted data allow to study in detail the invariant mass distribution of the Sigma(1385)^+. The mass distribution is well described by a relativistic Breit-Wigner function with a maximum at m_0 = 1383.2 +- 0.9 MeV/c^2 and a width of 40.2 +- 2.1 MeV/c^2. The exclusive production cross-section comes out to be 22.27 +- 0.89 +- 1.56 +3.07 -2.10 mu b. Angular distributions of the Sigma(1385)^+ in different reference frames are found to be compatible with the hypothesis that 33 % of Sigma(1385)^+ result from the decay of an intermediate Delta^{++} resonance.Comment: 12 pages; 12 figures; submitted to PR

Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Globally, group B Streptococcus (GBS) remains the leading cause of sepsis and meningitis in young infants, with its greatest burden in the first 90 days of life. Intrapartum antibiotic prophylaxis (IAP) for women at risk of transmitting GBS to their newborns has been effective in reducing, but not eliminating, the young infant GBS disease burden in many high income countries. However, identification of women at risk and administration of IAP is very difficult in many low and middle income country (LMIC) settings, and is not possible for home deliveries. Immunization of pregnant women with a GBS vaccine represents an alternate pathway to protecting newborns from GBS disease, through the transplacental antibody transfer to the fetus in utero. This approach to prevent GBS disease in young infants is currently under development, and is approaching late stage clinical evaluation. This manuscript includes a review of the natural history of the disease, global disease burden estimates, diagnosis and existing control options in different settings, the biological rationale for a vaccine including previous supportive studies, analysis of current candidates in development, possible correlates of protection and current status of immunogenicity assays. Future potential vaccine development pathways to licensure and use in LMICs, trial design and implementation options are discussed, with the objective to provide a basis for reflection, rather than recommendations